NCT05515458View on ClinicalTrials.gov

Pharmacokinetics of Chiglitazar in Subjects With Renal Impairment and Normal Renal Function

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 20, 2022

Primary Completion Date

July 19, 2023

Study Completion Date

July 19, 2023

Conditions
Renal Impairment
Interventions
DRUG

Chiglitazar

Oral single dose 48 mg

Trial Locations (1)

Unknown

the First Affiliated Hospital of Soochow University, Suzhou

Sponsors
All Listed Sponsors
lead

Chipscreen Biosciences, Ltd.

INDUSTRY